GSK4527226

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Alzheimer's Disease

Phase 2

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

TerminatedNCT06079190

GlaxoSmithKlineAlzheimer's Disease

Start: 2023-10-20End: 2026-08-18Updated: 2026-09-17

Open-label Extension Study in Participants With Early Alzheimer's Disease

RecruitingNCT07105709

GlaxoSmithKlineAlzheimer's Disease

Start: 2025-08-14End: 2028-12-08Target: 220Updated: 2026-02-02

Related Papers

Blood‐based biomarkers enrich for amyloid positive participants, reducing patient burden in PROGRESS‐AD, a phase 2 clinical trial for early Alzheimer's disease

Alzheimer s & Dementia2025-12-01

PROGRESS‐AD: a phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti‐sortilin monoclonal antibody, in patients with early Alzheimer’s disease

Alzheimer s & Dementia2024-12-01